

For Immediate Release

DIMERIX CHANGE OF ADDRESS AND CONTACT DETAILS

MELBOURNE, Australia, 12 November 2018: Dimerix Limited (ASX: DXB) advises that in accordance with ASX Listing Rule 3.14, from today the address of its registered office, place of business and mailing address has changed to:

Address: 425 Smith Street, Fitzroy 3065, Victoria
Telephone: 1300 813 321
Website: www.dimerix.com
Email: investor@dimerix.com

For further information, please visit our website at www.dimerix.com or contact the individuals outlined below.

—END—

At the Company
Dr Nina Webster Dimerix Limited
Chief Executive Officer
Tel: 1300 813 321
E: investor@dimerix.com

Investor Relations
Glen Zurcher IR Department
Account Director
Tel: +61 420 249 299
E: glen.zurcher@irdepartment.com.au

About Dimerix Bioscience Pty Ltd

Dimerix Limited's (ASX: DXB) wholly owned subsidiary Dimerix Bioscience Pty Ltd is a dynamic, clinical-stage drug development company, developing and commercialising patient-preferred and patent protected pharmaceutical products for global markets. Dimerix is currently developing its product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, termed Receptor-Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

For more information see www.dimerix.com